ADMA Biologics, Inc.

Total Valuation

ADMA Biologics, Inc. carries a market capitalization of 2.12B, placing it among publicly traded companies globally. Its enterprise value stands at 2.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ADMA Biologics, Inc. currently has 232.29M shares outstanding.

Valuation Ratios

ADMA Biologics, Inc. trades at a trailing price-to-earnings ratio of 13.00. The price-to-sales ratio is 4.22, and the price-to-book ratio stands at -18.48.

Enterprise Valuation

On an enterprise value basis, ADMA Biologics, Inc. trades at an EV/EBITDA multiple of 10.31 and an EV/FCF ratio of 14.30. The EV/Sales ratio of 4.35 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.71 provides insight into valuation relative to core operating earnings.

Financial Position

ADMA Biologics, Inc. maintains a current ratio of 6.95, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.37, indicating elevated leverage, while an interest coverage ratio of 29.69 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, ADMA Biologics, Inc. has paid 40.98M in income taxes, reflecting an effective tax rate of 19.86.

Stock Price Statistics

ADMA Biologics, Inc.'s stock has declined approximately -48.76957% over the past 52 weeks. The 50-day moving average sits at 8.83, while the 200-day moving average is 13.98.

Income Statement

Over the trailing twelve months, ADMA Biologics, Inc. generated 509.86M in revenue and converted that into 165.35M in net income, yielding earnings per share of 0.68. EBITDA reached 214.82M, while operating income came in at 206.86M.

Balance Sheet

ADMA Biologics, Inc. holds 138.15M in cash and equivalents against 204.41M in total debt, resulting in a net debt position of 58.71M. Total book value stands at -116.30M, with working capital of 437.63M providing operational flexibility.

Cash Flow

ADMA Biologics, Inc. produced 128.32M in operating cash flow over the past twelve months. After subtracting -20.77M in capital expenditures, free cash flow totaled 107.55M - equivalent to 0.45 per share.

Margins

ADMA Biologics, Inc. operates with a gross margin of 61.27, reflecting its pricing power and cost economics. The operating margin of 40.57 and net profit margin of 32.43 provide insight into operational efficiency.

Dividends & Yields

Scores

ADMA Biologics, Inc. posts an Altman Z-Score of 7.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.